Deisenhammer F - Search Results

1

Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS).

Fazekas F, Baumhackl U, Berger T, Deisenhammer F, Fuchs S, Kristoferitsch W, Ladurner G, Soukop W, Wimmer G, Vass K. Fazekas F, et al. Among authors: deisenhammer f. Eur J Neurol. 2010 Jun 1;17(6):852-60. doi: 10.1111/j.1468-1331.2009.02943.x. Epub 2010 Jan 20. Eur J Neurol. 2010. PMID: 20100231

2

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Fazekas F, et al. Among authors: deisenhammer f. Lancet. 1997 Mar 1;349(9052):589-93. doi: 10.1016/s0140-6736(96)09377-4. Lancet. 1997. PMID: 9057729 Clinical Trial.

3

[Clinical aspects and diagnosis of multiple sclerosis].

Berger T, Deisenhammer F. Berger T, et al. Among authors: deisenhammer f. Wien Med Wochenschr. 1996;146(19-20):504-13. Wien Med Wochenschr. 1996. PMID: 9082650 Review. German.

4

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Fazekas F, et al. Among authors: deisenhammer f. Mult Scler. 1997 Apr;3(2):137-41. doi: 10.1177/135245859700300214. Mult Scler. 1997. PMID: 9291168 Clinical Trial.

5

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750

6

Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.

Kaser A, Deisenhammer F, Berger T, Tilg H. Kaser A, et al. Among authors: deisenhammer f. Lancet. 1999 Apr 24;353(9162):1413-4. doi: 10.1016/S0140-6736(99)00622-4. Lancet. 1999. PMID: 10227230 No abstract available.

7

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Among authors: deisenhammer f. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.

8

A comparative study of the relative bioavailability of different interferon beta preparations.

Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. Deisenhammer F, et al. Neurology. 2000 Jun 13;54(11):2055-60. doi: 10.1212/wnl.54.11.2055. Neurology. 2000. PMID: 10851362 Clinical Trial.

9

The Austrian Immunoglobulin in MS (AIMS) study: final analysis.

Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B. Strasser-Fuchs S, et al. Among authors: deisenhammer f. Mult Scler. 2000 Oct;6 Suppl 2:S9-13. Mult Scler. 2000. PMID: 11188778 Clinical Trial.

10

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T. Deisenhammer F, et al. J Interferon Cytokine Res. 2001 Mar;21(3):167-71. doi: 10.1089/107999001750133195. J Interferon Cytokine Res. 2001. PMID: 11331039

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters